Trials Sponsors Conditions Drugs Pricing

Conditions

Osteonecrosis Due to Drugs, Jaw

Keywords

jaw osteonecrosisbiphosphonatesantiangiogenic agentsoral surgery

Outcome Measures

Primary Outcomes (1)

occurrence of osteonecrosis of the jaw
occurrence of osteonecrosis of the jaw
within 3 months after surgery

Secondary Outcomes (1)

Frequency of post-operative healing (bone and gingival) and comparison to each patient's UCONNS score.
within 3 months after surgery

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

patients who have received biphosphonates or antangiogenic drugs as part of chemotherapy with malignant bone disease (multiple myeloma or bone metastasis of a solid tumour) and who has had an oral surgical procedure (single or multiple dental extraction, with or without alveolectomy, under local or general anesthesia)

You may qualify if:

patients who have received at least one of the following molecules as part of chemotherapy with malignant bone disease (multiple myeloma or bone metastasis of a solid tumour):

Sponsors & Collaborators

Centre Hospitalier Sud Francilien
Otherlead

Study Sites (5)

Centre Hospitalier Intercommunal Robert Ballanger

Aulnay-sous-Bois, 93600, France

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, 91106, France

Centre Hospitalier Universitaire Henri Mondor

Créteil, 94010, France

Centre Hospitalier Bretagne Atlantique

Vannes, 56017, France

Institut Gustave Roussy

Villejuif, 94805, France

Related Publications (9)

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. doi: 10.1016/s0278-2391(03)00720-1. No abstract available.
PMID: 12966493RESULT
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007 Mar;65(3):369-76. doi: 10.1016/j.joms.2006.11.003. No abstract available.
PMID: 17307580RESULT

Study Officials

Emeline Noaillon, MD
Centre Hospitalier Sud Francilien
PRINCIPAL INVESTIGATOR

Enrollment

45 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 4, 2020

First Posted

February 6, 2020

Study Start

October 10, 2019

Actual (reported)

Study Stopped

Predictive Score For Maxillary Osteonecrosis After Invasive Oral Surgery

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

Related Publications (9)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

Related Publications (9)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations